0001104659-14-060259.txt : 20140813 0001104659-14-060259.hdr.sgml : 20140813 20140813110441 ACCESSION NUMBER: 0001104659-14-060259 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140813 FILED AS OF DATE: 20140813 DATE AS OF CHANGE: 20140813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOVARTIS AG CENTRAL INDEX KEY: 0001114448 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15024 FILM NUMBER: 141036248 BUSINESS ADDRESS: STREET 1: LICHTSTRASSE 35 CITY: BASEL STATE: V8 ZIP: CH 4056 BUSINESS PHONE: 01141613241111 MAIL ADDRESS: STREET 1: LICHTSTRASSE 35 CITY: BASEL STATE: V8 ZIP: CH 4056 6-K 1 a14-19000_16k.htm 6-K

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE

13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

 

Report on Form 6-K dated August 13, 2014

 

(Commission File No. 1-15024)

 

 

NOVARTIS AG

(Name of Registrant)

 

Lichtstrasse 35

4056 Basel

Switzerland

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F: x

 

Form 40-F: o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes: o

 

No: x

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes: o

 

No: x

 

 

 


 

Investors and others should note that we announce information that may be material to investors, including news and commentary about our research and development, regulatory matters, products, business and financial performance as well as notices of events for investors using:

 

·                  Filings with the US Securities and Exchange Commission (SEC);

·                  Press releases (posted to our Newsroom website at www.novartis.com/newsroom);

·                  Our investor relations website (www.novartis.com/investors);

·                  Public conference calls and webcasts;

·                  Our Twitter channel (twitter.com/novartis); and

·                  Our Facebook page (facebook.com/novartis).

 

We use these and other internet and social media channels to communicate with investors, employees, the medical community and the public about our products, our company and other issues.  It is possible that the information we post on social media could be deemed material information.  We encourage investors, the media and others interested in our company to review the information we post on these sites.  This list may be updated from time to time on the Novartis website.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

NOVARTIS AG

 

 

 

 

 

 

 

By:

/s/ HARRY KIRSCH

 

Name:

Harry Kirsch

 

Title:

Chief Financial Officer

 

 

 

 

 

 

 

By:

/s/ FELIX R. EHRAT

 

Name:

Felix R. Ehrat

 

Title:

General Counsel

 

 

Date: August 4, 2014

 

3